Impact of recommendations on the initial therapy of Parkinson's disease: A population-based study in France

Parkinsonism and Related Disorders

Volumn 17, Issue 7, 2011, Pages 543-546

  Fayard, Claudine ^a   Bonaventure, Audrey ^b,c   Benatru, Isabelle ^a   Roze, Emmanuel ^d   Dumurgier, Julien ^b,c,e   Moisan, Frédéric ^b,c   Soumaré, Aïcha ^b,c   Houssinot, Jean ^f   Dupupet, Jean Luc ^f   Mazurie, Jean Louis ^g   Balaboi, Irina ^h   Houeto, Jean Luc ^h   Krim, Elsa ⁱ   Ranoux, Danièle ^j   Goldberg, Marcel ^b,k,l   Imbernon, Ellen ^m   Moreau, Thibault ^a   Giroud, Maurice ^a   Tzourio, Christophe ^b,c   Elbaz, Alexis ^b,c  

^a UNIVERSITÉ DE BOURGOGNE   (France)

^b INSERM   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e HÔPITAL FERNAND WIDAL   (France)

^f Caisse Centrale de Mutualité Sociale Agricole   (France)

^g Caisse de Mutualité Sociale Agricole de Gironde   (France)

^h POITIERS UNIVERSITY HOSPITAL   (France)

ⁱ CENTRE HOSPITALIER DE PAU   (France)

^j LIMOGES UNIVERSITY HOSPITAL   (France)

^k LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^l UNIVERSITÉ PARIS SACLAY   (France)

^m INSTITUT DE VEILLE SANITAIRE   (France)

more..

Author keywords

Epidemiology; Guidelines; Medical practice; Parkinson's disease

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA;

ADULT; AGED; ARTICLE; CONSENSUS DEVELOPMENT; CONTROLLED STUDY; FEMALE; FRANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; PARKINSON DISEASE; PRIORITY JOURNAL; TREATMENT PLANNING;

AGED; ANTIPARKINSON AGENTS; CONSENSUS DEVELOPMENT CONFERENCES AS TOPIC; DOPAMINE AGONISTS; FEMALE; FRANCE; GUIDELINE ADHERENCE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC;

EID: 79960212790     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2011.04.020     Document Type: Article

References (17)

1. Encarnacion E.V., Hauser R.A. Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments. Eur Neurol 2008, 60:57-66.
2. Schrag A., Ben-Shlomo Y., Brown R., Marsden C.D., Quinn N. Young-onset Parkinson's disease revisited-clinical features, natural history, and mortality. Mov Disord 1998, 13:885-894.
3. Hely M.A., Morris J.G., Reid W.G., O'Sullivan D.J., Williamson P.M., Rail D., et al. The Sydney Multicentre Study of Parkinson's disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa. J Neurol Neurosurg Psychiatry 1994, 57:903-910.
4. Montastruc J.L., Rascol O., Senard J.M., Rascol A. A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up. J Neurol Neurosurg Psychiatry 1994, 57:1034-1038.
5. Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. BMJ 1993, 307:469-472. Parkinson's Disease Research Group in the United Kingdom.
6. Rinne U.K. Lisuride, a dopamine agonist in the treatment of early Parkinson's disease. Neurology 1989, 39:336-339.
7. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Jama 2000, 284:1931-1938. Parkinson Study Group.
8. Rinne U.K., Bracco F., Chouza C., Dupont E., Gershanik O., Marti Masso J.F., et al. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs 1998, 55(Suppl 1):23-30.
9. Rascol O., Brooks D.J., Korczyn A.D., De Deyn P.P., Clarke C.E., Lang A.E. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000, 342:1484-1491.
10. Parkinson's disease: diagnostic and therapeutic criteria. Consensus conference proceedings. Paris, France, 3 March 2000. Rev Neurol (Paris) 2000, 156(Suppl2 Pt2):7-294.
11. Bower J.H., Maraganore D.M., McDonnell S.K., Rocca W.A. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990. Neurology 1999, 52:1214-1220.
12. March 2000. http://www.has-sante.fr/portail/jcms/c_272069/la-maladie-de-parkinson-criteres-diagnostiques-et-therapeutiques.
13. December 2010. http://www.has-sante.fr/portail/jcms/c_418716/methodes-delaboration-des-recommandations-de-bonne-pratique.
14. Durocher A. Consensus conference: methodology and contribution. Therapie 1994, 49:185-190.
15. Rosa M.M., Ferreira J.J., Coelho M., Freire R., Sampaio C. Prescribing patterns of antiparkinsonian agents in Europe. Mov Disord 2010 Jun 15, 25:1053-1060.
16. Trifirò G., Savica R., Morgante L., Vanacore N., Tari M., Moretti S., et al. Prescribing pattern of anti-Parkinson drugs in Southern Italy: cross-sectional analysis in the years 2003-2005. Parkinsonism Relat Disord 2008, 14:420-425.
17. Askmark H., Antonov K., Aquilonius S.M. The increased utilisation of dopamine agonists and the introduction of COMT inhibitors have not reduced levodopa consumption-a nation-wide perspective in Sweden. Parkinsonism Relat Disord 2003, 9:271-276.